JPRN-UMIN000015375已完成未知
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea - Levofloxacin-containing sequential therapy in Korea
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 76years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) patients with previous H. pylori eradication therapy; (2) patients treated with H2 receptor antagonist, PPI, and antibiotics in the previous 4 weeks, or nonsteroidal anti-inflammatory drug (NSAID) in the previous 2 weeks; (3) pregnant or lactating women; (4) patients who suffered from serious diseases such as severe liver disease, renal disease, and cerebrovascular disease; (5) patients who had a drug allergy to the study drugs; and (6) patients with previous gastric surgery.
研究者
相似试验
已完成
不适用
Efficacy and Safety of treatment with Levofloxacin for Community-acquired PneumoniaCommunity-acquired pneumonia in adultsJPRN-UMIN000008677Second Division, Department of Internal Medicine, Hamamatsu university school of medicine300
招募中
不适用
Comparison of Levofloxacin/Colistin with Levofloxacin/high dose Ampicillin-sulbactam infusion in treatment of Ventilator-Associated Pneumonia due to multi drug resistant AcinetobacterIRCT20120703010178N15Shahid Beheshti University of Medical Sciences56
已完成
2 期
Comparing the effect of levofloxacin with azithromycin in improving pulmonary function of patients with bronchiectasisIRCT20100102002954N28Shahroud University of Medical Sciences72
招募中
1 期
Efficacy of levofloxacin and colistin inhalation form in treatment of pneumoniaVentilator associated pneumonia (VAP) caused by multidrug resistant pathogens.Ventilator associated pneumoniaJ95.851IRCT20100107003014N26Mazandaran University of Medical Sciences70
招募中
4 期
Pharmacokinetic study and safety of levofloxacin in pediatric tuberculosis treatmentMulti-drug resistant tuberculosisIsoniazid resistant tuberculosispatient with toxicity from the first line antituberculosisMDR-Hr-Toxicity from the first line anti-LevofloxacinTBTCTR20190515001Center of Excellence for Pediatric Infectious Diseases and Vaccines20